Slingshot Biosciences, Inc. Partners With Kem-En-Tec Nordic A/S to Distribute Synthetic Cells Throughout Denmark, Sweden, Norway, Finland, and Iceland
SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Kem-En-Tec Nordic A/S, Provider of Competent Bioscience products to the Nordic laboratories since 1987.
The agreement entitles Kem-En-Tec Nordic A/S to the right to distribute and resell Slingshot Bio’s products in Denmark, Sweden, Norway, Finland, and Iceland. Through Kem-En-Tec Nordic A/S’s network of customers, Slingshot Bio will be able to establish its presence in the Nordic market with the well-established presence and expertise of Kem-En-Tec Nordic A/S which has been selling into flow cytometry for many years.
“Kem-En-Tec Nordic A/S’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Kem-En-Tec Nordic A/S’s extensive knowledge in the field, prominent presence, and large customer base will help us leverage our position in the flow cytometry market,” said Jeffrey Kim, CEO & Founder.
Slingshot Bio’s synthetic cellular controls provide consistent, precise, and accurate control for research users in the flow cytometry space by mimicking blood properties as detected by flow cytometry. The ability to manufacture consistent controls for flow cytometry has been missing for decades and is now accurately reproducible with Slingshot Bio’s unique manufacturing platform. “Kem-En-Tec Nordic strongly believes that the innovative synthetic cell controls from Slingshot will be widely adopted by researchers using flow cytometry in all the Nordic countries,” said Henrik Tind Nielsen, CCO & Co-Owner at Kem-En-Tec Nordic.
About Slingshot Biosciences, Inc.
Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614006014/en/
Contact information
Slingshot Biosciences, Inc.
The Synthetic Cell Company
1250 45th St. Suite 330
Emeryville, CA 94608
510-770-6806
www.slingshotbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 22:46:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to working with health authorities to ensure all eligible patients who can benefit from vimseltinib have access as quickly as p
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 19:09:00 EEST | Press release
Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske
Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations17.9.2025 17:35:00 EEST | Press release
Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/ Bacardi announces new roles for Dave Ingram and Nicole Zukowski. Dave Ingram has been appointed to the role of Chief People & Business Transformation Officer, responsible for delivering the next chapter for building an organization that is fit for the future. In this role, Dave will continue to prioritize talent management, succession planning, performance management, and capability building which are core to setting a legacy of more than 163 years for the success of generations to come. Dave, a member of the Bacardi Global Leadership Team, most recently served as Chief Supply Chain Officer, where he led the end-to-end supply chain for the company’s po
Andersen Consulting Adds Collaborating Firm Charter17.9.2025 16:30:00 EEST | Press release
Andersen Consulting expands its digital transformation capabilities through a Collaboration Agreement with Charter, a Canadian consulting firm that specializes in IT strategy, managed services, and application delivery. Established in 1997, Charter delivers technology projects with a business-first mindset and deep technical expertise, offering IT advisory, cloud infrastructure, cybersecurity, application development, project delivery, and business architecture. Charter supports traditional enterprise, government, service provider, and mid-market clients with implementation, network infrastructure, and customer-facing applications—delivered through a lifecycle approach from strategy to execution. “Our goal at Charter has always been to remove the complexity from IT and help organizations move with confidence,” said Kelly Michell, president of Charter. “Our collaboration with Andersen Consulting enables us to bring our integrated, business-aligned solutions to new markets and continue d
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 16:10:00 EEST | Press release
Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025 Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value. Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom